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Director's Overview
Blinding eye diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma, affect millions of Americans of all ages and ethnicities. These and other less common diseases disable productive careers and rob people of their mobility and independence. NEI supports vision research through over 1,500 research grants and training awards made to scientists at more than 250 medical centers, hospitals, and universities across the country and around the world. NEI also conducts laboratory and patient-oriented research at its own facilities located on the NIH campus in Bethesda, Maryland.
Laying the Groundwork for Tomorrow's Medical Breakthroughs
NEI-supported research has made encouraging progress in developing stem cell therapies for common and rare eye diseases. Investigators recently isolated immune cells from human blood samples and created induced pluripotent stem (iPS) cells. The stem cells were manipulated to form structures resembling eye tissues, such as the neural retina and the retinal pigment epithelium (RPE). Since many blinding eye diseases are caused by degeneration of RPE and retinal neurons, it may one day be possible to generate replacement tissues for damaged eyes. Adult, human RPE can also be a source of stem cells. Biologists showed that a subpopulation of RPE cells from donor eyes could be induced to multiply and turn into other cell types, not just eye cells, but also brain, fat, and blood tissues.
The eye is filled with fluid, which is filtered and drained by a tissue at the base of the cornea called the trabecular meshwork. Blocked drainage can lead to elevated intraocular pressure-a key risk factor for glaucoma. Cochlin, a protein of unknown origin, was found in the trabecular meshwork and was shown to aggregate and change physical properties when fluid pressure increased. Using animal models of glaucoma, NEI researchers found that raising or lowering cochlin levels in trabecular cell membranes correlated with changes in intraocular pressure.
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These observations suggest that cochlin functions as an ocular mechanical stress sensor to regulate intraocular pressure, and that cochlin is a potential therapeutic target for glaucoma.
Translating Research Into Therapies NEI-supported investigators have developed a potential new treatment to prevent the most common complication of retinal detachment, a sight-threatening condition that requires prompt surgical treatment. Proliferative retinopathy (PVR) occurs in about 10 percent of retinal detachments, resulting in permanent scarring of the retina. In this condition, RPE cells migrate through the retinal detachment where they rapidly multiply on the surface of the retina. The RPE cells next contract and pull at the retina creating another detachment that results in heavy scarring of the retina and potential blindness. NEI investigators identified seven classes of biological growth factors and regulatory proteins that promote the proliferation and contraction of RPE cells in an animal model of PVR. By inhibiting the expression of these biological factors, the investigators prevented PVR, demonstrating proof-of-concept for a treatment to prevent this serious, sight-threatening complication of retinal detachment.
The cornea, the outer protective layer of the eye, is amazingly resilient to infection. Exposing cultured human corneal cells to bacteria led researchers to identify cytokeratin 6A-derived peptides, previously known to serve only as structural support, as important in corneal defense of bacterial infection. Blocking these peptides in a rodent model led to a marked increase in corneal infections. Synthetic variations of these peptides effectively killed bacteria that lead to flesh-eating disease and strep throat, staph infections, diarrhea, and cystic fibrosis lung infections. The findings could lead to a powerful new class of low-cost antibiotics.
A device that provides sight to the blind may sound like science fiction, but in October 2012 the Argus II Retinal Prosthesis System took a key step toward market approval when an FDA advisory panel voted unanimously (19-0) in favor of the system. Argus II consists of a miniature video camera that is inconspicuously mounted on a pair of sunglasses. A processing unit worn on a belt converts images captured by the camera into electrical impulses that are wirelessly transmitted to a 60-electrode grid implanted in the eye. Users perceive the electrical impulses as patterns of light that produce visual information. The device restores ambulatory vision to people who are blind from retinitis pigmentosa, a retinal degenerative disease. The Argus II, developed by Second Sight, Inc., was made possible through a decade of support from the Department of Energy and NEI.
The Power of Bioinformatics to Solve Vision Science Questions
The surge in high powered computing has enabled scientists to analyze immense amounts of data. Increased computing capacity, coupled with faster and cheaper methods of sequencing DNA, has revolutionized the search for factors that cause complex disease. NEI initiated an institutional research training program in Statistical Genetics and Genome Informatics to help meet a growing need for investigators trained in ophthalmologic computational genomics. Two institutions were awarded grants in FY 2011, and two more grants will be added to the program in FY 2013.
AMD is the leading cause of blindness in the U.S. NEI is proposing a new initiative in FY 2014 that will build on recent advances in genetics, imaging, and clinical testing techniques to identify distinct subgroups and the corresponding molecular mechanisms that cause this complex disease.
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Current evidence suggests that there are multiple biologic pathways that lead to the final stage of advanced AMD and vision loss (e.g., vascular, immunologic, and cholesterol). NEI proposes to use new high resolution imaging and visual function measurements combined with patient genetic information to identify AMD subgroups at various stages of the disease. These patients will be eligible to for expedited recruitment into prevention clinical trials and will help clinicians develop appropriate treatment strategies and personalized medicine.
Primary Open Angle Glaucoma (POAG) affects more than 2 million Americans and is the leading cause of blindness among Hispanic and African Americans. This year the NEI Glaucoma Human genetics collaboration (NEIGHBOR) published results from the largest ever glaucoma genome-wide association study, which identified two genetic regions associated with POAG. Current POAG drugs target intraocular pressure, a risk factor that leads to degeneration of the optic nerve in many patients. Significantly, the new genes are associated with neurodegeneration, the common endpoint of different types of glaucoma, opening the door to new avenues of therapy. NEI is now creating the NEIGHBOR Heritable Overall Operational Database consortium, whose goals are to expand the collection of glaucoma cases, to collect exacting clinical data for detailed classifications of POAG phenotypes, and to correlate them with genetic variations of the disease. 
Audacious Goals for Vision Research
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Funds are included in R&D contracts to support trans-NIH initiatives, such as the Basic Behavioral and Social Sciences Opportunity Network (OppNet).
Program Descriptions and Accomplishments
Corneal Diseases, Cataract, and Glaucoma Research: Corneal diseases, cataract, and glaucoma cause more visits to ophthalmologists than any other vision disorders. NEI supports research to address all three conditions.
• Corneal disease research. Corneal injuries, infections, and diseases can be extremely painful and require immediate medical attention. NEI grantees are exploring how infectious, inflammatory, and immunological processes affect the cornea and how the cornea heals after a wound. Important proteins that promote and deter wound healing have been identified, providing an opportunity to develop therapies that prevent or ameliorate corneal disease.
• Cataract research. Worldwide, cataracts are the leading cause of blindness. NEI cataract research seeks to understand the physiological basis of lens transparency at the cellular and molecular levels and investigates strategies to prevent cataract formation and progression.
• Glaucoma research. Glaucoma is a blinding disease that often results from increased intraocular pressure. NEI investigators aim to understand the complex genetic and biological factors that cause the disease and to develop treatments that protect optic nerves from the damage that leads to vision loss.
Budget Policy: The FY 2014 President's Budget estimate for these activities is $172.70 million, a decrease of $0.6 million or 0.4 percent below the FY 2012 Actual level. Program plans for FY 2014 include evaluating the possible use of anti-neovascular agents in the treatment of neovascular corneal disease. Results of the 10-year follow-up from Cornea Donor Study, which is comparing the viability of younger and older donor tissue, will be published in the spring of 2013. NEI grantees are studying the role of highly enriched proteins in the ocular lens (crystallins, connexins, and aquaporins) with particular focus on their role in cataract development. NEI-supported genome-wide association studies and related bioinformatics efforts will continue to explore the role of genetics and the environment on the development of glaucoma and to understand the differential response of individuals to glaucoma medications. Other projects include optic nerve regeneration and functional re-connection of the injured optic nerve to the brain.
Sensorimotor Disorders, Visual Processing, and Rehabilitation Research: NEI supports important research in sensorimotor control, visual processing, and rehabilitation for individuals with low vision.
• Sensorimotor disorder research. Strabismus (misalignment of the eyes) and amblyopia (known as "lazy eye") are common disorders that develop during childhood. Program goals center on gaining a better understanding of the neuromuscular control of gaze and the development of the visual system in children at high risk for these disorders.
• Visual processing research. Refractive errors, such as nearsightedness, farsightedness, and astigmatism, are commonly correctable with eye glasses or contact lenses in the U.S. but remain a tremendous economic and personal burden globally. Major goals of this
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program are to discover the biochemical pathways that govern eye growth and to uncover the risk factors associated with refractive errors. NEI-supported vision scientists seek to understand how the brain processes the visual information that floods our eyes, how neural activity is related to visual perception, and how the visual system interacts with cognitive and motor systems.
• Rehabilitation research. Low vision is the term used to describe chronic visual conditions that are not correctable by eye glasses or contact lenses. NEI supports rehabilitation research on improving the quality of life of persons with visual impairments by helping them maximize the use of remaining vision and by devising improved aids and strategies to assist those without useful vision.
Budget Policy: The FY 2014 President's Budget estimate for these activities is $144.8 million, a decrease of $0.5 million or 0.4 percent below the FY 2012 Actual level. FY 2014 program plans include pursuing research to identify genetic risk factors for strabismus, myopia, and other ocular diseases. The program also supports the Neuro-Ophthalmology Research Disease Investigator Consortium, a clinical trials network dedicated to diseases of the optic nerve. The Consortium is conducting a clinical trial to evaluate a drug therapy and weight loss in the treatment of idiopathic intracranial hypertension (IIH), which is common in obese women, causes severe headaches and vision loss due to increased pressure on the optic nerve. More than 100,000 Americans suffer with IIH. NEI-supported investigators are also uncovering the neural basis of facial recognition which will ultimately provide an understanding of face-blindness, a condition associated with autism spectrum disorders. Finally, LookTel, an NEI-supported Small Business Innovation Research grantee, has leveraged the power and portability of smart phones to develop and release a novel product that allows the blind and visually impaired to recognize everyday objects by using their iPhone camera. Users capture an image of an item and record an audio description. The LookTel Recognizer will then immediately recognize the item and play the audio description the next time the phone camera is pointed at it.
Retinal Diseases Research:
The light-sensitive retina is susceptible to many sight-threatening conditions, including age-related macular degeneration (AMD), diabetic retinopathy, retinopathy of prematurity, retinitis pigmentosa, Usher's syndrome, ocular albinism, retinal detachment, and uveitis (inflammation). The goals of this program are to increase the understanding of disease mechanisms that cause vision loss and to develop improved methods of prevention, diagnosis, and treatment. To meet these goals, NEI supports research on the cell biology, physiology, and immunology of the retina and on the role of gene expression, gene regulation, and the environment in retinal health and disease. NEI investigators have identified gene variants for many of these diseases and have made significant progress in discovering the underlying biological mechanisms of vision loss. are also linked to some kidney diseases. Therapies that more tightly regulate CFH expression could prevent vision loss in this common, blinding eye disease. This workshop will help unite kidney and eye researchers and immunologists. In addition, results from the Age-Related Eye Disease Study 2 (AREDS2), a multi-center study to evaluate the use of additional oral supplements for the treatment of AMD and cataract, will be published in the spring of 2013.
Results from the second year of the Comparison of AMD Treatments Trials (CATT), published in 2012, found that Lucentis and Avastin, two common drugs used in the treatment of AMD, were equally effective. Additional results found that monthly injections were no better than less frequent, as-needed injections, allowing patients to avoid the discomfort of unneeded eye injections of the drugs. NEI-supported investigators have developed a digitally automated diagnostic algorithm that screens for early signs of diabetic retinopathy with a high degree of accuracy. This technology will expand access to diabetic retinopathy screening in rural and underserved areas. NEI investigators have made significant progress in understanding disease mechanisms that result in vision loss and have established proof-of-concept in animal models for several novel therapies. In 2013, NEI will enhance its translational research program by increasing support of a grant mechanism, the R24, which is specifically designed to support collaborative, multidisciplinary research programs focused on translational research such as development of pharmacologic, gene-, and cell-based therapies and delivery systems.
Current research is evaluating a novel agent that inhibits neovascularization. The growth of abnormal blood vessels is a common cause of severe vision loss in diabetic retinopathy, age-related macular degeneration, and retinopathy of prematurity. Two other R24 awards are evaluating small molecules to treat Stargardt disease, an early onset form of macular degeneration. Another grant is evaluating novel drug delivery methods to the retina. NEI also supports grants to develop gene-based therapies for a common form of retinitis pigmentosa and Leber Hereditary Optic Neuropathy. Still another project is developing novel therapies to control the expression of the complement factor H gene. Variants in this gene account for half of all cases of AMD. Intramural Research: NEI conducts world-class research that explores clinical and translational studies concerned with the cause, prevention, and treatment of major eye diseases and vision disorders; cellular and molecular mechanisms of eye development, including the expression and function of genes within the eye; immunology and infectious diseases of the eye; mechanisms of visual perception by the brain; and the ability to guide movements under sensory control. The National Ophthalmic Disease Genotyping Network (eyeGENE), an NEI intramural collaboration with patients, clinicians, and investigators throughout the U.S., has expanded its operations by collecting more than 4,000 patient DNA samples. eyeGENE enables patients to receive a genetic diagnosis for many rare eye diseases in exchange for donating DNA samples for research and 
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